Tango Therapeutics Financial Results
Tango Therapeutics reported third quarter 2026 financial results, highlighting a strong cash position of $977.5 million. The company announced plans to initiate a pivotal Phase 3 study of vopimetostat plus daraxonrasib for front-line pancreatic cancer in the first half of 2027 following positive Phase 1/2 data.
“In 2026, Tango has made significant strides towards bringing vopimetostat to patients with pancreatic cancer. This progress is rooted first in the data. Last month at ESMO, we shared promising data from the combination of vopimetostat plus daraxonrasib that reinforced the potential of this program to raise the bar for patients with MTAP-deleted and RAS-mutant pancreatic cancer.”
Malte Peters, MD, President and Chief Executive Officer of Tango